Thomas Smith Score: 62
Analyst at
Leerink Partners
Avg Return (Buy)
How much profit would you make?
Calculates the average return of all BUY recommendations after exactly 1 year (or today if newer).
Note: Sell ratings are ignored here to focus on investment potential.
Calculates the average return of all BUY recommendations after exactly 1 year (or today if newer).
Note: Sell ratings are ignored here to focus on investment potential.
+216.8%
1 Year Cap
Win Rate
How often is the direction correct?
Percentage of trades that are currently profitable.
• Buy: Stock price went UP 📈
• Sell: Stock price went DOWN 📉
Percentage of trades that are currently profitable.
• Buy: Stock price went UP 📈
• Sell: Stock price went DOWN 📉
67%
6 W / 3 L
Target Met
How often was the target reached?
Hits vs. Total.
Hits vs. Total.
100%
5 W / 0 L
Precision Hit
How often precise (±3%)?
Hits vs. Total.
Hits vs. Total.
40%
2 W / 3 L
Bullseye Hit
How often perfect (±1%)?
Hits vs. Total.
Hits vs. Total.
40%
2 W / 3 L
High Conviction
The "Brave" Trades (>20% Upside)
Win Rate only for recommendations where the analyst predicted a massive move (>20%).
Shows if they are right when they bet big.
Win Rate only for recommendations where the analyst predicted a massive move (>20%).
Shows if they are right when they bet big.
50%
3 W / 3 L
Long Wins
Success rate for BUY ratings
How often is the analyst right when saying "Buy"?
(Price went UP).
How often is the analyst right when saying "Buy"?
(Price went UP).
67%
6 W / 3 L
Short Wins
Success rate for SELL ratings
How often is the analyst right when saying "Sell"?
(Price went DOWN).
How often is the analyst right when saying "Sell"?
(Price went DOWN).
0%
0 W / 0 L
Coverage & Price Targets
| Date | Stock | Signal | Target | Start Price | Best Price (1Y) | Accuracy | Current Price |
|---|---|---|---|---|---|---|---|
| Jun 02, 2026 |
X4 Pharmaceuticals Inc
XFOR
|
BUY |
$12.00
Est. +192%
|
$4.11 | $4.25 |
Pending
|
$4.00
-2.7%
|
| May 28, 2026 |
Equillium Inc
EQ
|
BUY |
$6.00
Est. +128%
|
$2.63 | $3.43 |
Pending
|
$2.81
+6.8%
|
| Mar 16, 2026 |
Eledon Pharmaceuticals Inc
ELDN
|
BUY |
$5.00
Est. +82%
|
$2.74 | $4.20 |
Pending
|
$3.57
+30.3%
|
| Jan 21, 2026 |
RAPT Therapeutics Inc
RAPT
|
BUY |
$58.00
Est. +1%
|
$57.57 | $58.02 |
Bullseye Hit (±1%)
|
$58.01
+0.8%
|
| Dec 01, 2025 |
Evommune, Inc.
EVMN
|
BUY |
$42.00
Est. +103%
|
$20.71 | $31.97 |
Pending
|
$19.83
-4.2%
|
| Jul 23, 2025 |
Abivax - ADR
ABVX
|
BUY |
$74.00
Est. +16%
|
$63.74 | $148.83 |
Target Met
|
$96.55
+51.5%
|
| Mar 28, 2025 |
Equillium Inc
EQ
|
BUY |
$1.00
Est. +150%
|
$0.40 | $2.69 |
Target Met
|
$2.81
+602.5%
|
| Nov 12, 2024 |
RAPT Therapeutics Inc
RAPT
|
BUY |
$2.00
Est. +15%
|
$1.74 | $42.39 |
Target Met
|
$58.01
+3233.6%
|
| May 21, 2024 |
Q32 Bio Inc.
QTTB
|
BUY |
$54.00
Est. +79%
|
$30.20 | $53.73 |
Bullseye Hit (±1%)
|
$12.64
-58.1%
|
X4 Pharmaceuticals Inc
XFOR
Jun 02, 2026
Signal & Target
BUY
$12.00
Start Price
$4.11
Best Price (1Y)
$4.25
Current Price
$4.00
Return
-2.7%
Equillium Inc
EQ
May 28, 2026
Signal & Target
BUY
$6.00
Start Price
$2.63
Best Price (1Y)
$3.43
Current Price
$2.81
Return
+6.8%
Eledon Pharmaceuticals Inc
ELDN
Mar 16, 2026
Signal & Target
BUY
$5.00
Start Price
$2.74
Best Price (1Y)
$4.20
Current Price
$3.57
Return
+30.3%
RAPT Therapeutics Inc
RAPT
Jan 21, 2026
Signal & Target
BUY
$58.00
Start Price
$57.57
Best Price (1Y)
$58.02
Current Price
$58.01
Return
+0.8%
Evommune, Inc.
EVMN
Dec 01, 2025
Signal & Target
BUY
$42.00
Start Price
$20.71
Best Price (1Y)
$31.97
Current Price
$19.83
Return
-4.2%
Abivax - ADR
ABVX
Jul 23, 2025
Signal & Target
BUY
$74.00
Start Price
$63.74
Best Price (1Y)
$148.83
Current Price
$96.55
Return
+51.5%
Equillium Inc
EQ
Mar 28, 2025
Signal & Target
BUY
$1.00
Start Price
$0.40
Best Price (1Y)
$2.69
Current Price
$2.81
Return
+602.5%
RAPT Therapeutics Inc
RAPT
Nov 12, 2024
Signal & Target
BUY
$2.00
Start Price
$1.74
Best Price (1Y)
$42.39
Current Price
$58.01
Return
+3233.6%
Q32 Bio Inc.
QTTB
May 21, 2024
Signal & Target
BUY
$54.00
Start Price
$30.20
Best Price (1Y)
$53.73
Current Price
$12.64
Return
-58.1%